"Confidential and Proprietary" Document Proposes Plan for National Network

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

A story is told that after first obtaining approval for marketing Premarin in 1942, Wyeth Laboratories didn’t lock up the secret recipe for making the hormonal drug in a company safe, to be guarded by patent lawyers.

January 23, 2026

By Claire Marie Porter

Capitol Hill

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

The U.S. House of Representatives Jan. 22 passed a three-bill minibus package that is expected to be the grand finale of the drama of the fiscal year 2026 appropriations process. The package, which funds the HHS as well as the departments of Defense, Transportation, Housing and Urban Development, Labor, and Education, gives NIH and NCI modest raises over FY25, and nullifies several aggressive cuts the White House had proposed for NIH.

January 23, 2026

By Jacquelyn Cobb

Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community

Prostate cancer remains a formidable challenge, particularly in its advanced stages, where bone metastases and treatment resistance dominate outcomes. At City of Hope, our focus is on leveraging immunotherapy to transform this landscape.

January 23, 2026

By Tanya Dorff

In the Archives

Bernie Lewinsky’s collection of artifacts captures “the learning curve” of radiation oncology

Over his five decades as a radiation oncologist, Bernie Lewinsky has been collecting the relics of radiotherapy.

January 23, 2026

By Sara Willa Ernst

Cancer Policy

NIH ends fetal tissue research—again

NIH will no longer fund scientific research that uses human fetal tissue from elective abortions, a practice that has contributed to the study of cancer, the development of vaccines, and the treatment of other diseases.

January 23, 2026

By Sara Willa Ernst

Cancer Policy

ACA Marketplace enrollments down by 1.4 million, early data shows

According to a preliminary tally, 1.4 million fewer Americans have signed up for health insurance through the Affordable Care Act Marketplace this year, according to early data published by the Centers for Medicare and Medicaid Services.

January 23, 2026

By Sara Willa Ernst

“Confidential and Proprietary” Document Proposes Plan for National Network

YOU MAY BE INTERESTED IN

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community

Bernie Lewinsky’s collection of artifacts captures “the learning curve” of radiation oncology

NIH ends fetal tissue research—again

ACA Marketplace enrollments down by 1.4 million, early data shows

Renew today!

Subscriber content

Never miss an issue!

Login

“Confidential and Proprietary” Document Proposes Plan for National Network

YOU MAY BE INTERESTED IN

Premarin’s 84-year hold on the market ends as FDA approves a generic versionTrade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

Spending bill passed by the House gives NIH $415M raise, NCI gets $128MLegislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community

Bernie Lewinsky’s collection of artifacts captures “the learning curve” of radiation oncology

NIH ends fetal tissue research—again

ACA Marketplace enrollments down by 1.4 million, early data shows

Never miss an issue!

Login

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched